1. Liu, C, Wang, Y, Shi, J, et al. The status and progress of first-line treatment against Helicobacter pylori infection: a review. Therap Adv Gastroenterol 2021; 14: 1756284821989177.
Google Scholar | SAGE Journals2. Kalfus, IN, Graham, DY, Riff, DS, et al. Rifabutin-containing triple therapy (RHB-105) for eradication of Helicobacter pylori: randomized ERADICATE Hp trial. Antibiotics 2020; 9: 685.
Google Scholar | Crossref3. Graham, DY, Canaan, Y, Maher, J, et al. Rifabutin-based triple therapy (RHB-105) for Helicobacter pylori eradication: a double-blind, randomized, controlled trial. Ann Intern Med 2020; 172: 795–802.
Google Scholar | Crossref | Medline4. Gisbert, JP . Rifabutin for the treatment of Helicobacter pylori infection: a review. Pathogens 2021; 10: 15.
Google Scholar | Crossref5. Gisbert, JP, Calvet, X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2012; 35: 209–221.
Google Scholar | Crossref | Medline | ISI6. Heep, M, Beck, D, Bayerdorffer, E, et al. Rifampin and rifabutin resistance mechanism in Helicobacter pylori. Antimicrob Agents Chemother 1999; 43: 1497–1499.
Google Scholar | Crossref | Medline | ISI7. Crabol, Y, Catherinot, E, Veziris, N, et al. Rifabutin: where do we stand in 2016. J Antimicrob Chemother 2016; 71: 1759–1771.
Google Scholar | Crossref | Medline8. Li, J, Munsiff, SS, Driver, CR, et al. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000. Clin Infect Dis 2005; 41: 83–91.
Google Scholar | Crossref | Medline